HK Stock Market Move | BIODLINK-B (01875) surged more than 9%. WUXI XDC has obtained 60% of the company's equity and the acquisition tender offer has officially taken effect.

BIODLINK-B (01875) rose by more than 9%, closing at an increase of 8.02% as of the time of the report, at 4.85 Hong Kong dollars, with a turnover of 198.09 million Hong Kong dollars. On the news front, on March 18, WUXI XDC announced that the company had successfully acquired 60% of the equity of Dongyao Pharmaceutical. The acquisition offer has officially taken effect. According to WUXI XDC, the deadline for accepting the final offer of the acquisition is 4:00 pm on March 31, 2026, and Dongyao Pharmaceutical shareholders will decide whether to accept the offer during the remaining time. The final result of the offer will be announced before 7:00 pm on March 31, 2026. As early as January of this year, WUXI BIO, WUXI XDC, and Dongyao Pharmaceutical jointly announced that WUXI XDC plans to acquire all the issued shares of Dongyao Pharmaceutical through a cash offer, with a total price of approximately 3.091 billion Hong Kong dollars (approximately RMB 2.762 billion), making it the first major M&A deal in the CXO industry at the beginning of the year.